All In Biotech

Drug Trial Radar · NCT05207865

Safety and Tolerability Study of Daily Dosing Rimegepant in Episodic Migraine Prevention

A Phase 4, Open-label Study to Evaluate the Safety and Tolerability of Daily Dosing of Rimegepant in Episodic Migraine Prevention

Last checked: Nov 20, 2026Latest source record: Sep 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

441

Actual

Start

Mar 15, 2022

Primary completion

Jul 2, 2024

Study completion Jul 2, 2024

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Jan 26, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to further evaluate the long-term safety and tolerability of daily dosing of rimegepant for the prevention of episodic migraine.

Conditions

  • Migraine
  • Episodic Migraine
  • Phonophobia
  • Photophobia

Interventions

  • RimegepantDrug

    rimegepant ODT 75mg daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With On-Treatment Adverse Events (AEs) (Frequency >=5%) According to IntensityTime frame: From start of study treatment (Day 1) up to 7 days after the last dose of study treatment (Up to 25 weeks)
  2. Number of Participants With On-Treatment Serious Adverse Events (SAEs)Time frame: From start of study treatment (Day 1) up to 7 days after the last dose of study treatment (Up to 25 weeks)
  3. Number of Participants With AEs Leading to Study Drug DiscontinuationTime frame: From start of study treatment (Day 1) up to 7 days after the last dose of study treatment (Up to 25 weeks)
  4. Number of Participants With Grade 3 to 4 Laboratory Abnormalities On-Treatment Using Common Technical Criteria for Adverse Events- Division of Acquired Immune Deficiency Syndrome (CTCAE/DAIDS) Toxicity Grading ScaleTime frame: From start of study treatment (Day 1) up to 7 days after the last dose of study treatment (Up to 25 weeks)
  5. Number of Participants With Grade 3 to 4 Laboratory Abnormalities On-Treatment Using Food and Drug Administration (FDA) Toxicity Grading ScaleTime frame: From start of study treatment (Day 1) up to 7 days after the last dose of study treatment (Up to 25 weeks)

Locations

19 sites in 1 country. Site status is shown where the registry gives one.

  • Elite Clinical Studies, LLC

    Phoenix, Arizona

  • Advanced Investigative Medicine, Inc.

    Hawthorne, California

  • Velocity Clinical Research - North Hollywood

    North Hollywood, California

  • Chase Medical Research, LLC

    Waterbury, Connecticut

  • Phoenix Medical Research, LLC

    Miami, Florida

  • The Headache Clinic

    Alexandria, Louisiana

  • Boston Clinical Trials

    Boston, Massachusetts

  • Michigan Head Pain & Neurological Institute

    Ann Arbor, Michigan

  • CVS HealthHub - East Brunswick

    East Brunswick, New Jersey

  • CVS HealthHub - Lawrenceville

    Lawrenceville, New Jersey

  • CVS HealthHUB - Runnemede

    Runnemede, New Jersey

  • SPRI Clinical Trials, LLC

    Brooklyn, New York

  • Velocity Clinical Research

    Cincinnati, Ohio

  • OK Clinical Research, LLC

    Edmond, Oklahoma

  • Clinical Research Philadelphia, LLC

    Philadelphia, Pennsylvania

  • WR-ClinSearch, LLC

    Chattanooga, Tennessee

  • VIP Trails

    San Antonio, Texas

  • VIP Trials

    San Antonio, Texas

  • Tidewater Integrated Medical Research

    Virginia Beach, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.